HomeQuestion

What were your Top Takeaways in ILD from ACR Convergence 2025?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Is it still significant to denote the etiology of ILD in a patient with PPF?

How would you approach rituximab dosing in a patient with SLE-Myositis overlap with LN Class III, now with worsening UPCR and concern for worsening ILD 4 months post induction and incomplete B-Cell depletion on recent labs?

22 Answers

Do you recommend maintaining the same monitoring interval of PFTs every 3–6 months with HRCT as indicated for patients with anti-MDA5 dermatomyositis, or do you recommend closer surveillance in this group?

3 Answers

What minimum clinical features or risk factors drive you to obtain a baseline HRCT in a patient with RA or Sjogren's disease?

2 Answers

What findings on routine monitoring PFTs prompt you to pursue HRCT in your patients with SARDs?

2 Answers

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service